Parent Led Implementation of a VR Social Skills Training Program for Children With ASD
Effectiveness of Parent Led Implementation of a Virtual Reality Social Skills Training Program for Children With Autism Spectrum Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Krestin Radonovich, PhD
- Phone Number: 304-598-4300
- Email: krestin.radonovich@hsc.wvu.edu
Study Locations
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26508
- West Virginia University
-
Contact:
- Krestin Radonovich, PhD
- Phone Number: 304-598-4300
- Email: krestin.radonovich@hsc.wvu.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients or legally authorized representatives must provide written informed consent and be willing and able to comply with study procedures. Participants must provide informed assent as clinically appropriate.
- A diagnosis of autism spectrum disorder on the basis of the clinical judgement of a qualified clinician according to DSM-5 criteria, supported by either the Autism Diagnostic Observation Schedule or the Autism Diagnostic Interview-Revised.
- Participants must be able to tolerate VR therapy in the judgement of parent or caregiver and study staff.
- Female participants must either be unable to become pregnant (e.g., premenarchal, surgically sterile, etc.) or agree to use a highly effective method of contraception (e.g., intrauterine device, oral contraceptives, condom or diaphragm with spermicides, contraceptive sponge) from 28 days before the Baseline Visit to 45 days after the last treatment session. Females of childbearing potential must have a negative urine human chorionic gonadotropin pregnancy test at the Screening Visit.
Exclusion Criteria:
- History of photosensitive epilepsy or demonstrated photoparoxysmal response on prior electroencephalogram.
- Active diagnosis of migraine headache or migraine variant (abdominal migraine, cyclic vomiting syndrome) which is not adequately controlled by medication or other therapy.
- History of balance disorder including vertigo, motion sensitivity, or ataxia. Vestibular sensory deficits are not necessarily exclusionary.
- Primary sensory impairment (blindness, deafness).
- Motor disorder that would interfere with VR engagement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Floreo BSC
Subjects and their caregiver will engage in the Floreo VR Building Social Connections VR sessions: three sessions per week, for 12 weeks.
Each session will consist of 2 VR (Floreo BSC) lessons separated by a brief break, for a total of approximately 15 minutes of direct VR time over a 30-minute period.
Treatment sessions will be scheduled over a 12-week period, with an allowance of up to 15 weeks for make-up sessions (e.g., illness or travel).
|
The intervention will consist of two episodes of the Floreo BSC program, each lasting 4-5 minutes, according to a fixed program of episodes determined by the participant's color-coded group.
VR episodes will be presented via the Floreo application downloaded onto an iPhone worn by the participant in the VR headset.
The VR interaction will be controlled and operated via linked iPad.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Autism Impact Measure (AIM)
Time Frame: Baseline to 1 week post final treatment visit
|
Change in measure: The AIM is a 25-item parent questionnaire targeting sensitivity to change of core ASD symptoms (Kanne et al., 2014).
The questionnaire uses a 2-week recall period with items rated on two corresponding 5-point scales (frequency and impact).
5-point Likert-type scale, once for frequency of a specific behavior of the dependent and once for impact of that behavior.
Response options range from "never" to "always" for the frequency dimension and "not at all" to "severely" for the impact dimension.
Higher domain and higher total scores indicate greater symptom severity (Houghton et al., 2019; Mazurek et al., 2018).
Likewise, lower AIM scores indicate less severe symptomatology.
|
Baseline to 1 week post final treatment visit
|
|
Childhood Autism Rating Scale, 2nd Edition (CARS-2)
Time Frame: Baseline to 1 week post final treatment visit
|
Change in score from Baseline up to 1 week post final treatment visit.
The CARS2 total raw score range from 15 to 60.
This scale is a behavior rating scale intended to diagnose autism.
A total score of 15 indicates that an individual behavior is within normal limits, whereas a value of 60 indicates that the individual's behavior is severely abnormal.
|
Baseline to 1 week post final treatment visit
|
|
Vineland Scales of Adaptive Behavior, 3rd Edition (Vineland 3)
Time Frame: Baseline to 1 week post final treatment visit
|
Change in Measure for The Vineland-3 which evaluates adaptive behavior in five different domains: Social, Communication, Daily Living Skills, and Motor (Sparrow et al., 2016).
In the context of this study, it will be administered using the Comprehensive Interview Form, for which a parent or caregiver is interviewed by a qualified rater familiar with the instrument.
Based on the summarized scores in each domain, an Adaptive Behavior Composite (ABC) is also calculated.
Items are scored on a scale of 0 (never), 1 (sometimes), or 2 (usually) for the level at which the child can independently perform a skill.
The higher the score, the better the adaptive level.
|
Baseline to 1 week post final treatment visit
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Krestin Radonovich, PhD, West Virginia University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2304763205
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.